Phaseline

Targets › FSHR

FSHR (Follicle-stimulating hormone receptor): drug programs, companies and trials

10 programs from 8 companies in 14 trials: 5 Phase 4, 4 Phase 2, 3 Phase 3, 2 Phase 1; Genitourinary, Other, Oncology; next expected readout Dec 2026.

G protein-coupled receptor for follitropin, the follicle-stimulating hormone. Mediates FSH signaling through cAMP/protein kinase A (PKA) and phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT) pathways to regulate ovarian follicular development and steroidogenesis. (UniProt, P23945)

Open in Phaseline: the race on FSHR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Fundación Santiago Dexeus FontFollitropin-delta (Rekovelle) 15 mcg/day
Recombinant follicle-stimulating hormone (rFSH)
FSHRPhase 4FertilityDec 2026
Fundación Santiago Dexeus FontrhFSH+rhLH (Pergoveris®)
Recombinant human follicle-stimulating hormone and recombinant human luteinizing hormone
FSHR, LHRPhase 4InfertilityAug 2027
University Hospital, GhentCorifollitropin Alfa
Follicle stimulating hormone receptor agonist
FSHRPhase 4Ovarian StimulationDec 2027
LG ChemFang Le Shu (Follitrope)
Recombinant follicle-stimulating hormone (rFSH)
FSHRPhase 4Female Infertility–
Merck KGaAFollitropin (MBJ-0011)
Follicle stimulating hormone receptor agonist
FSHRPhase 3InfertilitySep 2027
Granata BiohMG (human menopausal gonadotropin)
Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) receptor agonist
FSHR, LHRPhase 3Infertility (IVF Patients)Nov 2028
Clinique OvoFollitropin Delta
Follicle stimulating hormone receptor agonist
FSHRPhase 2IVF; Low Ovarian Reserve; InfertilityAug 2027
Clinique OvoHP-hMG (MENOPUR)
Highly purified human menopausal gonadotrophin containing FSH and LH
FSHR, LHCGRPhase 2IVFAug 2027
Institut Cancerologie de l'OuestFSH (Follicle-stimulating hormone)
Recombinant gonadotropin that stimulates ovarian follicle development and oocyte maturatio
FSHRPhase 2Breast CancerJan 2028
Qilu PharmaceuticalFollitropin Alfa
Follicle stimulating hormone receptor agonist
FSHRPhase 1Infertility, Female–

Conditions

Infertility (5) IVF (2) Fertility (1) Low Ovarian Reserve (1) Ovarian Stimulation (1) Breast Cancer (1) Infertility, Female (1) Female Infertility (1) Infertility (IVF Patients) (1)

Modalities

small molecule (9), protein or peptide (1)

Companies

Fundación Santiago Dexeus Font (2) Clinique Ovo (2) University Hospital, Ghent (1) Institut Cancerologie de l'Ouest (1) Qilu Pharmaceutical (1) LG Chem (1) Granata Bio (1) Merck KGaA (1)

Related targets

LHR (2) LHCGR (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.